Immunitas Therapeutics logo
VerifiedBiotechnology Research· Founded 2019

Immunitas Therapeutics

Immunitas is committed to discovering and developing novel, differentiated therapeutics for patients with cancer and autoimmune diseases. Our lead program, IMT-009, targets CD161 and is in clinical trials for patients with refractory tumors across a variety of indications including MSS Colorectal Cancer, Head and Neck Cancer, and Non-Small Cell Lung Cancer. Our second program is a novel therapeutic for the treatment of autoimmune disease that builds on our specialized foundational knowledge of the CD161-CLEC2D pathway.

7-day free trial · no credit card

HeadquartersWaltham, United StatesEmployees25(11 to 50)Founded year2019Websiteimmunitastx.comLinkedIn profileLinkedIn

Verified contacts

25

available on Kipplo

LinkedIn employees

25

11 to 50 range

Open roles

no listings

Distinct roles

16

indexed titles

Tech stack

4

tools in use

Monthly traffic

80

organic / mo

Sign up free to see all 25 verified contacts at Immunitas Therapeutics

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Decision-makers and verified team members

25 contacts with verified email or phone · masked until revealed.

Sign up free →

Top roles at Immunitas Therapeutics

16 distinct titles indexed · top 10 shown.

  • 3discovery immunology co-op
  • 1(,)
  • 1- ()
  • 1board observer
  • 1chief executive officer
  • 1computational biologist
  • 1computational biology co-op
  • 1director, head of antibody discovery
  • 1director, head of discovery and pharmacology
  • 1executive assistant
  • +6more titles

Sign up to unlock all 25 contacts at Immunitas Therapeutics

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Sign up to reveal 25 verified contacts at Immunitas Therapeutics

7-day trial · no credit card · cancel anytime · only pay for verified records.

Trusted by sales, marketing, and GTM engineering teams.

Immunitas Therapeutics | Kipplo Discover